Get the Stockscreener App
79.83
1.48%
-1.185
Inhibrx Biosciences Inc stock is traded at $79.83, with a volume of 83,198.
It is down -1.48% in the last 24 hours and up +39.32% over the past month.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.
See More
Previous Close:
$81.01
Open:
$81.2
24h Volume:
83,198
Relative Volume:
0.24
Market Cap:
$1.16B
Revenue:
$1.80M
Net Income/Loss:
$1.76B
P/E Ratio:
0.6726
EPS:
118.674
Net Cash Flow:
$-149.23M
1W Performance:
+2.87%
1M Performance:
+39.32%
6M Performance:
+520.65%
1Y Performance:
+437.11%
1-Day Range:
$79.16
$81.46
1-Week Range:
$77.41
$87.83
52-Week Range:
$10.80
$87.83
Inhibrx Biosciences Inc Stock (INBX) Company Profile
Name
Inhibrx Biosciences Inc
Sector
Industry
Phone
(858) 795-4220
Address
11025 N. TORREY PINES ROAD, SUITE 140, LA JOLLA
Compare INBX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
INBX
Inhibrx Biosciences Inc
|
80.00 | 1.18B | 1.80M | 1.76B | -149.23M | 118.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
429.04 | 107.58B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
782.48 | 80.03B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
430.84 | 57.37B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
907.72 | 55.83B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
207.36 | 44.13B | 447.02M | -1.18B | -906.14M | -6.1812 |
Inhibrx Biosciences Inc Stock (INBX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-23-24 | Initiated | JMP Securities | Mkt Perform |
| Jan-23-24 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Mar-16-22 | Initiated | SMBC Nikko | Outperform |
| Sep-21-21 | Initiated | JMP Securities | Mkt Outperform |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Sep-14-20 | Initiated | Credit Suisse | Outperform |
| Sep-14-20 | Initiated | Evercore ISI | Outperform |
View All
Inhibrx Biosciences Inc Stock (INBX) Latest News
Inhibrx Biosciences stock hits all-time high at 87.4 USD By Investing.com - Investing.com Australia
Inhibrx Biosciences stock hits all-time high at 87.4 USD - Investing.com India
Discipline and Rules-Based Execution in INBX Response - news.stocktradersdaily.com
Will Inhibrx Biosciences Inc. stock deliver shareholder value2025 Key Highlights & Free Real-Time Volume Trigger Notifications - newser.com
What high frequency data says about Inhibrx Biosciences Inc.2025 Market Sentiment & Risk Adjusted Buy and Sell Alerts - newser.com
How high can Inhibrx Biosciences Inc. stock go2025 Valuation Update & Risk Controlled Stock Pick Alerts - newser.com
Multi factor analysis applied to Inhibrx Biosciences Inc.Weekly Gains Report & Weekly Watchlist for Hot Stocks - newser.com
Inhibrx Biosciences Inc. stock daily chart insights2025 Technical Patterns & Free Community Supported Trade Ideas - newser.com
How to recover losses in Inhibrx Biosciences Inc. stock2025 Market Outlook & Safe Capital Growth Tips - newser.com
Inhibrx Biosciences stock rating maintained at Market Perform by Citizens - Investing.com South Africa
Is Inhibrx Biosciences Inc. stock a buy in volatile marketsWeekly Trend Recap & Verified Stock Trade Ideas - newser.com
Will Inhibrx Biosciences Inc. stock pay special dividendsJuly 2025 Recap & Fast Gain Swing Alerts - newser.com
Inhibrx Biosciences Inc (INBX) Clearly Signals Buy-Into the Stock: Don’t ignore the signals - Setenews
Why Inhibrx Biosciences Inc. stock appeals to analystsJuly 2025 Price Swings & Daily Chart Pattern Signal Reports - newser.com
What Wall Street predicts for Inhibrx Biosciences Inc. stock priceQuarterly Trade Summary & Weekly Top Gainers Trade List - newser.com
Press Release: Inhibrx Reports Third Quarter 2025 Financial Results - 富途牛牛
Inhibrx Misses Estimates Even As New Cancer Drug Shows Promise - Finimize
Inhibrx Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025 - MarketScreener
Earnings Flash (INBX) Inhibrx Biosciences Posts Q3 Loss $2.28 a Share - MarketScreener
Inhibrx Biosciences' Q3 net loss widens, misses EPS estimates - MarketScreener
Inhibrx Biosciences, Inc. SEC 10-Q Report - TradingView
Inhibrx Reports Third Quarter 2025 Financial Results - PR Newswire
[8-K] Inhibrx Biosciences, Inc. Reports Material Event | INBX SEC FilingForm 8-K - Stock Titan
[10-Q] Inhibrx Biosciences, Inc. Quarterly Earnings Report | INBX SEC FilingForm 10-Q - Stock Titan
Inhibrx’s Phase 2 Study on INBRX-109: A Potential Breakthrough in Chondrosarcoma Treatment - MSN
Inhibrx supports CTOS2025 spotlight on chondrosarcoma - Traders Union
Behavioral Patterns of INBX and Institutional Flows - news.stocktradersdaily.com
What does recent volatility data suggest for Inhibrx Biosciences Inc.Quarterly Profit Review & Consistent Income Trade Ideas - newser.com
Is Inhibrx Biosciences Inc. stock resilient to inflationEarnings Overview Summary & Accurate Intraday Trading Signals - newser.com
Tick level data insight on Inhibrx Biosciences Inc. volatilityJuly 2025 Recap & AI Enhanced Trading Alerts - newser.com
Will Inhibrx Biosciences Inc. stock benefit from sector rotation2025 AllTime Highs & Free Daily Entry Point Trade Alerts - newser.com
Inhibrx Biosciences Inc Stock (INBX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.50%
1.41%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):